AOD-9604: Research, Mechanism, and What the Evidence Actually Shows

What Is AOD-9604?

AOD-9604 is a synthetic peptide fragment derived from the C-terminal end of human growth hormone. It has been studied primarily for its effects on fat metabolism.

AOD-9604 stands for Anti-Obesity Drug 9604. It consists of amino acids 176–191 from human growth hormone, with an added tyrosine residue at the N-terminus. In practical terms, researchers took the full growth hormone protein and isolated just the small tail-end region believed to be responsible for breaking down fat. The rest of the molecule — the parts that promote tissue growth, raise blood sugar, and affect organ size — was deliberately left out.

The rationale was straightforward: keep the fat-burning signal, discard everything else.

Developed at Monash University in Australia by Metabolic Pharmaceuticals (now Calzada Ltd.), AOD-9604 advanced through Phase II clinical trials for obesity before development stalled. In 2010, it received GRAS (Generally Recognized as Safe) designation from the FDA as a food supplement ingredient. This status reflects safety data, not proven efficacy for fat loss. The FDA was saying the compound appears safe to consume, not that it works for weight management.

This page provides a neutral summary of the available research, including results that were less favorable than the peptide community often acknowledges.

Who this page is for, and who it isn’t for

This page is for researchers, clinicians, and individuals who want an honest summary of what is known about AOD-9604 from published studies. It is not a buying guide, a protocol recommendation, or a substitute for medical advice. If you are considering any peptide for fat management, consult a qualified healthcare provider.

How AOD-9604 Is Thought to Work

AOD-9604 is believed to promote fat breakdown through pathways that mimic the lipolytic portion of growth hormone signaling. Importantly, it does not activate the growth hormone receptor itself.

What “GH Fragment” Actually Means

Human growth hormone is a large protein with many effects throughout the body. Some regions of the molecule promote tissue growth. Others influence blood sugar. The C-terminal region — the tail end, amino acids 176–191 — appears to be involved in fat metabolism specifically.

AOD-9604 is a synthetic copy of just that tail-end region. Think of it as photocopying one chapter from a long book. You get the fat metabolism instructions without the growth-promoting, insulin-disrupting, or organ-enlarging chapters. This is why researchers call it a “GH fragment” — it is literally a fragment of the larger growth hormone protein.

Lipolytic Pathway

Lipolysis is the process of breaking stored fat into fatty acids that the body can use for energy. When researchers say AOD-9604 has “lipolytic activity,” they mean it appears to accelerate this fat-breakdown process.

Preclinical research suggests AOD-9604 acts through the following mechanisms:

• Beta-3 adrenergic receptor engagement. AOD-9604 appears to enhance signaling through beta-3 adrenergic receptors, which are predominantly found on fat cells. These receptors act like switches that tell fat cells to release their stored energy. Studies in mice that lacked beta-3 receptors showed a blunted response to AOD-9604, supporting this pathway (Heffernan et al., 2001). This matters because it suggests AOD-9604 needs these specific receptors to work — it is not triggering fat breakdown through some nonspecific mechanism.

• Hormone-sensitive lipase activation. The peptide increases activity of hormone-sensitive lipase (HSL). HSL is the rate-limiting enzyme in triglyceride breakdown within fat tissue. In simpler terms, HSL is the molecular tool that actually cuts stored fat into usable pieces. By boosting HSL activity, AOD-9604 may accelerate the speed at which stored fat is mobilized.

• Inhibition of lipogenesis. AOD-9604 also appears to reduce the formation of new fat. This is a separate effect from breaking down existing fat. The peptide may work on both sides of the equation: increasing fat breakdown while decreasing fat creation.

Why It Doesn’t Act Like Growth Hormone

A critical distinction: AOD-9604 does not bind to the growth hormone receptor (GHR) and does not raise IGF-1 levels. This means it does not trigger the growth-promoting, insulin-disrupting, or organ-enlarging effects associated with full-length growth hormone (Ng & Bornstein, 2000).

Why this matters: full-length growth hormone carries significant side effects including insulin resistance, water retention, carpal tunnel syndrome, and at high doses, abnormal organ growth. By using only the fat-metabolism fragment, AOD-9604 appears to avoid this entire category of risk. This clean separation is the central design principle behind the peptide.

No Observed Effect on Blood Sugar

Unlike full-length GH — which opposes insulin and can contribute to insulin resistance — AOD-9604 has shown no effect on blood glucose or insulin levels in multiple studies. This metabolic neutrality is one of its most consistently demonstrated properties.

This is especially relevant because many people interested in fat loss peptides are also managing metabolic health. A compound that helps with fat but worsens blood sugar would undermine its own purpose. AOD-9604 does not appear to have this problem.

Emerging Cartilage Research

More recently, investigators have explored AOD-9604’s effects on cartilage cells. In vitro and animal studies suggest it stimulates proteoglycan and collagen synthesis in chondrocytes. Proteoglycans and collagen are the structural building blocks of cartilage, so this finding has led to early-stage research into potential joint health applications.

Some Australian clinics have explored intra-articular injection for osteoarthritis. However, robust clinical evidence for this use is not yet available [research needed].

What the Research Shows

The evidence for AOD-9604 includes a Phase IIb clinical trial that failed its primary endpoint, stronger preclinical animal data, and a well-established safety record. Understanding the gap between the animal results and the human results is essential to evaluating this peptide honestly.

The Phase IIb Clinical Trial (The Key Study)

The largest human study was a 24-week, randomized, double-blind, placebo-controlled trial. It involved approximately 300 obese adults who received oral AOD-9604 at multiple dose levels.

The result was disappointing. The primary endpoint — body weight reduction compared to placebo — was not met at most dose levels. One dose group showed a small but statistically significant reduction in fat mass. However, the overall clinical effect was considered insufficient for drug development to continue (Stier et al., 2013).

This is the central tension with AOD-9604: the largest human trial did not demonstrate clinically meaningful weight loss. The peptide community frequently emphasizes preclinical data and the mechanism of action while understating this result.

Preclinical Animal Data

The animal evidence is considerably more encouraging:

• Obese mice: AOD-9604 reduced body fat by approximately 50% over 19 days without affecting lean mass or food intake (Heffernan et al., 2001).
• Obese Zucker rats: Chronic treatment reduced adiposity.
• Human fat cells in the lab: Lipolytic activity was confirmed in isolated human adipocyte cultures.

These results are striking. A 50% fat reduction in mice is dramatic. However, the gap between dramatic animal results and modest human outcomes is a recurring challenge in pharmaceutical development. Mice have different metabolic rates, different fat distribution, and different receptor densities than humans. AOD-9604 is a textbook example of this translational problem.

Why this matters: when evaluating any peptide, impressive animal data does not guarantee human results. AOD-9604 is one of the clearest demonstrations of this principle in the peptide world.

Cartilage and Joint Data

Emerging research from in vitro and animal models suggests AOD-9604:

• Stimulates proteoglycan synthesis in human cartilage cells
• Promotes chondrocyte proliferation
• May support cartilage repair in osteoarthritis models

This line of research is preliminary but has generated interest in orthopedic applications. No large-scale human joint studies have been published to date [research needed].

GRAS Safety Determination

The FDA GRAS determination (2010) was based on extensive safety and toxicology data documenting:

• No carcinogenicity
• No mutagenicity
• No reproductive toxicity
• No effect on insulin or glucose metabolism
• Good tolerability across multiple dose levels

This safety profile is arguably AOD-9604’s strongest documented attribute. While the efficacy story is mixed, the safety story is consistently positive.

Claimed Benefits vs. What Evidence Supports

It is important to distinguish between benefits supported by published data and those reported anecdotally. The two categories differ substantially for AOD-9604.

Supported by Published Research

• No negative effects on blood sugar. Consistently demonstrated across multiple studies. This is well-established.
• Favorable safety profile. Supported by GRAS status and extensive toxicology data.
• Lipolytic activity in preclinical models. Demonstrated in cell culture and animal studies. The mechanism is plausible and the preclinical evidence is real.
• Potential cartilage support. Preliminary evidence from in vitro and animal research only.

Community-Reported (Limited or No Published Support)

• Localized fat reduction from injecting near target areas. There is no scientific validation for site-specific fat reduction via injection. Peptides enter systemic circulation regardless of where they are injected.
• Meaningful body composition changes. Community reports exist, but the Phase IIb trial data did not support clinically significant effects.
• Joint pain improvement. Some user reports are consistent with the cartilage research direction, but controlled human data is lacking.

An Honest Assessment

AOD-9604’s fat loss effects in humans appear modest at best based on the Phase IIb data. It is not comparable to semaglutide or tirzepatide — both of which have produced 15–20% body weight reductions in large clinical trials. It is not even comparable to a well-structured caloric deficit.

Its appeal lies primarily in its safety profile and the absence of GH-related side effects. This may make it a low-risk addition to a fat loss program for some individuals. But “low risk” should not be confused with “highly effective.” See our guide to fat loss peptides for a broader comparison.

Community-Reported Protocols

Community-reported protocols suggest the following approaches, which should not be interpreted as recommendations.

Subcutaneous Injection

• Reported dose: 250–300 mcg per day
• Reported timing: Morning, in a fasted state (at least 30 minutes before food)
• Reported cycle length: Up to 12 weeks
• Injection site: Subcutaneous, typically abdominal area. Community members sometimes prefer proximity to target fat deposits, though systemic distribution occurs regardless of injection site.

Timing Considerations

Community protocols commonly emphasize:

• Injecting in a fasted state, on the rationale that low insulin levels may enhance lipolytic signaling
• Waiting 30–60 minutes post-injection before eating
• Avoiding injection after meals, when insulin is elevated

Reconstitution

• Typically supplied as 5 mg lyophilized vials
• Reconstituted with 2 mL bacteriostatic water (yielding 2,500 mcg/mL)
• 0.12 mL = approximately 300 mcg
• Stored refrigerated; generally used within 4 weeks after reconstitution

Side Effects and Safety Considerations

AOD-9604’s safety record is one of the best-documented aspects of this peptide, based on clinical trial data and the GRAS determination.

Reported Side Effects

• Injection site reactions. Mild redness and occasional discomfort. This is typical of subcutaneous injection in general, not specific to AOD-9604.
• Headache. Infrequently reported.
• Mild nausea. Rarely reported.

The overall side effect burden is minimal. Most users in clinical trials reported no adverse effects beyond what was observed in the placebo group.

What AOD-9604 Does Not Appear to Cause

In contrast to full-length growth hormone and GH secretagogues such as ipamorelin or CJC-1295:

• No insulin resistance or blood sugar disruption
• No water retention
• No carpal tunnel symptoms
• No organ enlargement
• No IGF-1 elevation
• No acromegaly risk

This clean side effect profile is the primary reason AOD-9604 continues to attract interest despite the equivocal efficacy data. For people who want to explore fat-metabolism peptides without the risks associated with growth hormone itself, AOD-9604 represents one of the lowest-risk options available.

Open Questions

• Long-term safety of ongoing subcutaneous use has not been rigorously studied. The GRAS determination covered oral consumption as a food ingredient, not chronic injection.
• The cartilage effects, while potentially beneficial, have not been evaluated for safety in long-duration protocols.

How AOD-9604 Compares to Other Fat Loss Peptides

Understanding where AOD-9604 fits relative to other compounds studied for fat loss helps calibrate expectations.

• Semaglutide and tirzepatide are GLP-1 receptor agonists with robust Phase III evidence showing 15–20%+ body weight reduction. They work through appetite suppression and metabolic pathways entirely different from AOD-9604. They also carry significant GI side effects and lean mass loss concerns.

• Tesamorelin is an FDA-approved GHRH analog with demonstrated efficacy for visceral fat reduction (approximately 18% by CT measurement). It works through GH release and carries a moderate side effect profile.

• Ipamorelin + CJC-1295 as GH secretagogues promote general lipolysis through GH elevation. They offer broader anabolic and recovery effects but require fasted dosing and carry some insulin sensitivity considerations.

• AOD-9604 occupies a unique niche: very low risk, very low side effects, but also the weakest human efficacy data in this group.

For a fuller comparison, see our best peptides for fat loss guide.

Regulatory and Legal Status

United States

AOD-9604 holds FDA GRAS status as a food ingredient, not as a drug. It is not approved for any therapeutic indication. It is available as a research chemical and through some anti-aging and compounding pharmacies.

Australia

Developed in Australia, AOD-9604 has seen wider clinical use there, particularly through practitioners exploring joint health applications via intra-articular injection.

WADA

AOD-9604 is prohibited under WADA Section S2 — growth hormone fragments are explicitly banned in competitive sport.

Frequently Asked Questions

Does AOD-9604 actually work for fat loss in humans?

Based on the largest available human trial, the effects are modest. The Phase IIb trial did not meet its primary endpoint of clinically meaningful weight loss. Animal data is more impressive, but the translation to humans was poor. AOD-9604 is best understood as a potential adjunct to diet and exercise, not a standalone fat loss solution.

How does AOD-9604 compare to semaglutide for fat loss?

They are not comparable in magnitude. Semaglutide produces approximately 15% body weight loss in clinical trials with thousands of patients. AOD-9604’s human efficacy data is far weaker. AOD-9604’s advantage is its superior safety profile and lack of GI side effects. The two peptides work through completely different mechanisms.

Can injecting AOD-9604 near belly fat cause spot reduction?

There is no scientific evidence supporting localized fat reduction through site-specific injection. AOD-9604 enters systemic circulation regardless of injection site.

Why does AOD-9604 remain popular despite the failed clinical trial?

Several factors contribute: its well-established safety profile, the compelling mechanistic rationale, strong preclinical data, effective marketing by peptide vendors, and community anecdotal reports. Some users may also experience synergy with diet and exercise programs, placebo effects, or individual variation not captured by the clinical trial.

Is AOD-9604 safe long-term?

The GRAS determination and clinical trial data provide a strong safety foundation. AOD-9604 is widely considered one of the safer peptides available. However, long-term data from continuous subcutaneous use specifically is limited. The GRAS status was based on oral consumption as a food ingredient, which is a different route of administration.

Can AOD-9604 help with joint health?

Emerging preclinical data suggests potential cartilage-supportive effects, and some Australian clinics have used intra-articular injections for osteoarthritis. However, no controlled human trials have been published for this application. See also our guide on peptides for injury recovery.

References

1. Ng FM, Bornstein J. “Hyperglycemic action of synthetic C-terminal fragment of human growth hormone.” Am J Physiol. 2000;279(5):E1293-E1300. PubMed
2. Stier H, et al. “Safety and tolerability of the hexadecapeptide AOD9604 in humans.” J Endocrinol Invest. 2013;36(5):283-90. PubMed
3. Heffernan MA, et al. “The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice.” Endocrinology. 2001;142(12):5182-9. PubMed
4. Thomas A, et al. “Characterization of the growth hormone releasing activity of AOD9604.” Regulatory Peptides. 2000;87(1-3):47-51.
5. Metabolic Pharmaceuticals. “Phase IIb Clinical Trial Results for AOD9604.” Company reports, 2007. [research needed — direct publication link]
6. Australian Register of Therapeutic Goods. AOD-9604 intra-articular formulation documentation. [research needed]

Related Articles

Peptide

CJC-1295: What the Evidence Says About This GHRH Analog

An evidence-first review of CJC-1295, covering how it differs from native GHRH, DAC vs no-DAC variants, clinical trial data, and what the research shows about GH stimulation.

Peptide

Ipamorelin: What the Evidence Says About This Selective GH Secretagogue

An evidence-first review of ipamorelin, covering its selectivity compared to other GHRPs, what clinical and preclinical research has demonstrated, and what remains unknown.

Peptide

Semaglutide: What the Clinical Evidence Shows About This GLP-1 Agonist

A comprehensive, evidence-first review of semaglutide (Ozempic/Wegovy) — clinical trial data on weight loss and cardiovascular outcomes, mechanism of action, side effects, and practical considerations.